Scarica l'app Stockscreener
7.67
0.00%
0.00
Precedente Chiudi:
$7.67
Aprire:
$7.85
Volume 24 ore:
957.39K
Relative Volume:
1.10
Capitalizzazione di mercato:
$494.88M
Reddito:
$89.40M
Utile/perdita netta:
$-221.30M
Rapporto P/E:
-2.3554
EPS:
-3.2564
Flusso di cassa netto:
$-256.90M
1 W Prestazione:
+8.18%
1M Prestazione:
-12.64%
6M Prestazione:
-32.00%
1 anno Prestazione:
+2.68%
Intervallo 1D:
$7.52
$8.02
Intervallo di 1 settimana:
$7.08
$8.02
Portata 52W:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.67 | 494.88M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-10-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-09-24 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-06-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Downgrade | Truist | Buy → Hold |
| 2025-05-02 | Downgrade | Jefferies | Buy → Hold |
| 2025-05-02 | Downgrade | TD Cowen | Buy → Hold |
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Arvinas (ARVN) CSO has shares sold automatically to cover RSU tax withholding - Stock Titan
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas Inc (ARVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arvinas Inc (ARVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arvinas Inc (ARVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arvinas Inc (ARVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arvinas Inc (ARVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arvinas Inc (ARVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arvinas (NASDAQ: ARVN) insider sells 2,642 shares; May sale of 9,657 noted - Stock Titan
Rigel to roll out Veppanu in August; Arvinas, Pfizer snag $70M upfront on cleared deal - MSN
Pfizer trades up with Rigel’s Veppanu deal done - TechStock²
According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a - Bitget
Arvinas, Pfizer receive $70M upfront as Rigel deal for VEPPANU clears HSR - TradingView
Arvinas (NASDAQ: ARVN) secures $70M VEPPANU payment and major milestones - Stock Titan
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant) - Yahoo Finance
Price-Driven Insight from (ARVN) for Rule-Based Strategy - Stock Traders Daily
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas sharpens pipeline focus after first PROTAC approval, eyes key trial data - MSN
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data - MarketBeat
Arvinas joins MJFF initiatives to advance LRRK2 research - BioWorld News
Arvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's Disease - marketscreener.com
Arvinas, Inc. Joins The Michael J. Fox Foundation's LITE And PPMI Programs To Advance New Therapies Targeting LRRK2 For Parkinson's Disease - marketscreener.com
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI - GlobeNewswire
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
ARVN Reiterates by Stephens & Co. -- Price Target Maintained at $18 - GuruFocus
ARVN: First PROTAC degrader approved; pipeline prioritization and key milestones drive focus - TradingView
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development - The Globe and Mail
ArvinasAnnounces Re-Prioritization Of Portfolio Following Strategic ReviewSEC Filing - TradingView
Arvinas reprioritizes pipeline, to complete ARV-806 Phase 1 data and seek out-license; cash runway into H2 2028 - TradingView
Arvinas (ARVN) refocuses ARV-806 strategy and projects cash runway into second half of 2028 - Stock Titan
(ARVN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Full Transcript: Arvinas Q1 2026 Earnings Call - Benzinga
Monaco Asset Management SAM Has $833,000 Holdings in Arvinas, Inc. $ARVN - MarketBeat
Arvinas to Present at Jefferies Global Healthcare Conference - The Manila Times
Arvinas, Inc. to Participate in Fireside Chat at Jefferies Global Healthcare Conference on June 3, 2026 - Quiver Quantitative
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock By Investing.com - Investing.com India
Rigel Pharmaceuticals director Ali-Jackson Kamil sells $72,925 in stock - Investing.com
Arvinas Inc. (ARVN) Stabilizes Near Support Amid Biotech Sector CautionVolatility Skew - thelegaladvocate.com
Arvinas Q1 earnings call highlights - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN) - The Globe and Mail
Arvinas (ARVN) CEO reports small automatic share sale for RSU tax withholding - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Barclays Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Arvinas (NASDAQ: ARVN) insider sells shares; RSU settlement reported - Stock Titan
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.74%
1.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):